FilingReader Intelligence
RemeGen licenses eye drug to Santen for $1.3bn
August 18, 2025 at 11:49 PM UTC•By FilingReader AI
RemeGen granted Santen China exclusive rights to develop and commercialize RC28-E Injection for retinal diseases across Greater China, South Korea and Southeast Asia.
The deal includes 250 million yuan upfront, up to 1.045 billion yuan in milestones, plus tiered sales royalties. RC28-E treats ocular neovascular diseases.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
HKEX:9995•Hong Kong Exchange
News Alerts
Get instant email alerts when RemeGen, publishes news
Free account required • Unsubscribe anytime